Live
Cadila Healthcare has signed an agreement with Supernus Pharmaceuticals for settling a patent litigation regarding Trokendi XR extended release capsules that are used in treatment of seizures.
Cadila Healthcare has said in a BSE filing that the company along with subsidiary Zydus Pharmaceuticals (USA) Inc, have finalised an agreement with Supernus Pharmaceuticals Inc to settle all outstanding patent litigation related to Trokendi XR (topiramate) extended-release capsules.
It further said that under the terms of the pact, Supernus grants a license for marketing Zydus’ generic version of Trokendi XR (topiramate) extended-release capsules beginning on January 1, 2023, or earlier, under certain circumstances.
